Psychiatry and Neurology, Neurology · Cheshire, CT
NPI
1649454976
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
6
Hospital affiliations
280 South Main Street, Suite 102
Cheshire, CT, 06410
Phone (860) 870-6385
Groups this clinician bills Medicare through
Medicare paid, 2024
$417K
65,950 services
Medicare patients, 2024
327
Average age 75
Drug cost, 2024
$5.6M
6,018 prescriptions
Company payments, 2025
$8,122
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Duarte G Machado was code J0585 (injection, onabotulinumtoxina, 1 unit), 37,603 times for 49 patients. In total Duarte G Machado billed 65,950 services in 25 codes, and Medicare paid $417K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 37,603 | 49 | $4.97 | $187K |
| J0588 Injection, incobotulinumtoxin a, 1 unit | Office | 23,400 | 33 | $4.10 | $96K |
| 99214 Office E&M - Established | Office | 332 | 223 | $104.94 | $35K |
| 64616 Musculoskeletal | Office | 121 | 34 | $158.20 | $19K |
| 99205 Office E&M - New | Office | 45 | 45 | $194.28 | $8,743 |
| 64642 Musculoskeletal | Office | 44 | 16 | $117.79 | $5,183 |
| 95983 Electrical Nerve Conductivity | Office | 40 | 18 | $40.21 | $1,609 |
| 99213 Office E&M - Established | Office | 39 | 24 | $67.79 | $2,644 |
| 64644 Musculoskeletal | Office | 33 | 13 | $143.19 | $4,725 |
| 11105 Skin Biopsy | Office | 32 | 17 | $53.27 | $1,705 |
| 64611 Musculoskeletal | Office | 28 | 13 | $113.54 | $3,179 |
| 99204 Office E&M - New | Office | 26 | 26 | $126.34 | $3,285 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 24 | 22 | $14.23 | $342 |
| 64612 Musculoskeletal | Office | 23 | 12 | $129.64 | $2,982 |
| 64643 Musculoskeletal | Office | 23 | 11 | $82.95 | $1,908 |
By year: 2022 $467K for 81,407 services; 2023 $430K for 73,457 services; 2024 $417K for 65,950 services.
Medicare prescription drug claims, 2024
In 2024, the drug Duarte G Machado prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 581 prescriptions and refills. In total Duarte G Machado wrote 6,018 Medicare prescriptions that cost $5.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 581 | 1,333 | 196 | $22K |
| Clonazepam Generic | 372 | 490 | 81 | $2,947 |
| Gabapentin Generic | 307 | 509 | 78 | $5,832 |
| Rytary Carbidopa/Levodopa | 279 | 461 | 63 | $377K |
| Rivastigmine Rivastigmine Tartrate | 212 | 376 | 58 | $12K |
| Primidone Generic | 208 | 516 | 58 | $5,386 |
| Gocovri Amantadine Hcl | 183 | 215 | 30 | $565K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 166 | 427 | 72 | $4,168 |
| Amantadine Amantadine Hcl | 165 | 324 | 56 | $11K |
| Diazepam Generic | 141 | 150 | 16 | $1,217 |
| Baclofen Generic | 140 | 215 | 32 | $2,852 |
| Pregabalin Generic | 114 | 130 | 22 | $1,674 |
| Quetiapine Fumarate Generic | 111 | 169 | 26 | $1,875 |
| Nourianz Istradefylline | 108 | 128 | 21 | $242K |
| Ongentys Opicapone | 107 | 137 | 26 | $93K |
Brand drugs: - claims; generic drugs: 4,371 claims; opioid claims: 82.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Duarte G Machado $8,122 ($8,122 in general payments such as food, travel and fees) from 12 companies. The largest payer was MDD US Operations, LLC with $3,975.
| Company | Payments | Amount |
|---|---|---|
| MDD US Operations, LLC | 32 | $3,975 |
| Medtronic, Inc. MDT | 12 | $2,624 |
| Abbvie Inc. ABBV | 27 | $549 |
| Pfizer Inc. PFE | 14 | $322 |
| Supernus Pharmaceuticals, Inc. SUPN | 11 | $170 |
| Teva Pharmaceuticals USA, Inc. TEVA | 6 | $149 |
| Merz Pharmaceuticals, LLC | 2 | $125 |
| ACADIA Pharmaceuticals Inc ACAD | 3 | $105 |
| Neurocrine BioSciences, Inc. NBIX | 1 | $37.98 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 1 | $25.65 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.